or Try an Advanced Search...

    Technical Analysis for LABP - Landos Biopharma, Inc.

    Grade Last Price % Change Price Change
    B 22.21 0.16% 0.04
    LABP closed up 0.16 percent on Wednesday, May 8, 2024, on 19 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    Earnings due: May 10
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Extremely Strong Up Up Flat
    Historical LABP trend table...
    Date Alert Name Type % Chg
    Bollinger Band Squeeze Range Contraction 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Bollinger Band Squeeze Range Contraction 0.16%
    NR7 Range Contraction 0.16%
    NR7-2 Range Contraction 0.16%
    Narrow Range Bar Range Contraction 0.16%
    Bollinger Band Squeeze Range Contraction 0.25%
    NR7 Range Contraction 0.25%
    Older End-of-Day Signals for LABP ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 13 hours ago
    60 Minute Opening Range Breakdown about 15 hours ago
    60 Minute Opening Range Breakdown 1 day ago
    10 DMA Resistance 1 day ago
    Possible NR7 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    LABP Chart by TradingView
    Basic chart:

    Profile

    Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Inflammatory Bowel Disease Gastroenterology Ulcerative Colitis Abdominal Pain Colitis Crohn's Disease Diarrhea Diabetic Nephropathy

    Is LABP a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 26 Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
    Mar 28 Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs
    Mar 26 AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio
    Mar 25 Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?
    Mar 25 Landos shares rocket 170% on AbbVie takeover deal
    Mar 25 AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
    Mar 25 AbbVie to buy immune drug developer Landos
    Mar 21 Landos Biopharma reports Q4 results
    Mar 21 Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results
    Mar 5 Will Landos Biopharma (NASDAQ:LABP) Spend Its Cash Wisely?
    See more LABP news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.84
    52 Week Low 2.5
    Average Volume 27,802
    200-Day Moving Average 7.24
    50-Day Moving Average 16.37
    20-Day Moving Average 22.03
    10-Day Moving Average 22.29
    Average True Range 0.38
    RSI (14) 82.96
    ADX 76.97
    +DI 44.06
    -DI 9.43
    Chandelier Exit (Long, 3 ATRs) 21.69
    Chandelier Exit (Short, 3 ATRs) 22.58
    Upper Bollinger Bands 22.67
    Lower Bollinger Band 21.38
    Percent B (%b) 0.64
    BandWidth 5.84
    MACD Line 1.38
    MACD Signal Line 1.84
    MACD Histogram -0.4537
    Fundamentals Value
    Market Cap 69.21 Million
    Num Shares 3.12 Million
    EPS -3.85
    Price-to-Earnings (P/E) Ratio -5.77
    Price-to-Sales 2.37
    Price-to-Book 0.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 22.34
    Resistance 3 (R3) 22.32 22.27 22.31
    Resistance 2 (R2) 22.27 22.23 22.27 22.31
    Resistance 1 (R1) 22.24 22.21 22.25 22.25 22.30
    Pivot Point 22.18 22.18 22.19 22.18 22.18
    Support 1 (S1) 22.15 22.14 22.16 22.16 22.11
    Support 2 (S2) 22.09 22.12 22.10 22.10
    Support 3 (S3) 22.06 22.09 22.10
    Support 4 (S4) 22.07